JPMorgan Chase & Co. Has Lowered Expectations for Dyne Therapeutics (NASDAQ:DYN) Stock Price

Dyne Therapeutics (NASDAQ:DYN) had its price objective cut by research analysts at JPMorgan Chase & Co. from $17.00 to $16.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 8.57% from the company’s previous close.

A number of other analysts also recently weighed in on the company. Wall Street Zen downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, December 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a report on Monday, December 8th. Finally, Royal Bank Of Canada increased their target price on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.41.

Dyne Therapeutics Stock Up 5.5%

Shares of NASDAQ DYN opened at $17.50 on Tuesday. The company has a 50 day simple moving average of $19.41 and a 200 day simple moving average of $15.64. The firm has a market cap of $2.50 billion, a PE ratio of -4.78 and a beta of 1.32. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $25.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. On average, research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC increased its stake in shares of Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after acquiring an additional 1,900 shares in the last quarter. Chung Wu Investment Group LLC bought a new position in Dyne Therapeutics during the third quarter worth $30,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares during the period. Ameritas Investment Partners Inc. increased its stake in Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after purchasing an additional 955 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the period. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.